Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 7;21(41):11740-7.
doi: 10.3748/wjg.v21.i41.11740.

Neuroendocrine differentiation: The mysterious fellow of colorectal cancer

Affiliations
Review

Neuroendocrine differentiation: The mysterious fellow of colorectal cancer

Britta Kleist et al. World J Gastroenterol. .

Abstract

Neuroendocrine differentiation in sporadic colorectal cancer has been recognized since decades, but its clinical impact is still controversially discussed. Detailed parameter analyses hint at the possibility that probably not neuroendocrine differentiation itself, but its association with poor grade of tumor differentiation, lymph node metastases, distant metastases and other unfavorable features contribute to worse clinical outcome. However, other studies deny a relationship between neuroendocrine differentiation and prognosis of colorectal cancer. This review elucidates, whether new insights into the origin of neuroendocrine differentiation in the intestinal epithelium, its regulation by mTOR pathway components and its possible link to the intestinal stem cell compartment could determine a role of neuroendocrine cells as prognostic marker and putative therapeutic target in sporadic colorectal cancer.

Keywords: Colorectal cancer; Neuroendocrine differentiation; Neuroendocrine tumorigenesis; Targeted therapy; mTOR pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The PI3K/PTEN/Akt/mTOR-cascade (Modified according to Cingarlini et al[29] and McCubrey et al[32]). Phosphatidylinositol-3-kinase (PI3K) is a heterodimeric protein with an p85-kDA regulatory subunit and a p110α-kDa catalytic subunit (PIK3CA). PI3K phosphorylates membrane phospholipids, thereby forming the second messenger lipids phosphatidylinositol 3,4-biphosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate (PIP3). Pleckstrin-homology (PH) domain of kinase Akt binds to PIP3, thereby promoting activation of Akt via phosphorylation by phosphotidylinositide-dependent kinase 1 (PDK1, not displayed in the Figure). Akt inhibits tuberous sclerosis 2 (TSC2 or tuberin) function through direct phosphorylation. TSC2 phosphorylation by Akt represses activity of the TSC1/TSC2 complex, allowing the small GTPase Rheb to activate the protein kinase function of mTOR (mammalian target of rapamycin). mTOR forms the catalytic core of the mTORC1 complex, which comprises additionally Raptor (Regulatory associated protein of mTOR) adaptor protein, DEPTOR (DEP domain containing mTOR-interacting protein), mLST8 (member of the Lethal-with-Sec-Thirteen gene family), FKBP38 (FK506 binding protein 38), and PRAS40 (proline-rich Akt substrate 40 kDa protein). Activated mTOR phosphorylates p70S6K, which induces a negative feedback loop uncoupling IRS-1 (insulin receptor substrate-1) from PI3K, thus preventing further signal transduction through this pathway. Negative regulation of the PI3K pathway is primarily accomplished though the PTEN tumor suppressor protein, which dephosphorylates phosphoinositide substrates as PIP3. Expression of PTEN is regulated by microRNA miR-21.
Figure 2
Figure 2
Primary colorectal cancer with focal synaptophysin expression (magnification × 200).

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
    1. Kelly C, Cassidy J. Chemotherapy in metastatic colorectal cancer. Surg Oncol. 2007;16:65–70. - PubMed
    1. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009;14:478–488. - PubMed
    1. Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal? Eur J Cancer. 2009;45:2452–2461. - PubMed
    1. Kim JC, Kim SY, Cho DH, Ha YJ, Choi EY, Kim CW, Roh SA, Kim TW, Ju H, Kim YS. Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin Cancer Res. 2011;17:1200–1209. - PubMed

MeSH terms